Source: Annual Congress 2001 - Factors contributing to upper and lower airway responses
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. M. Salagean, C. Eames, L. Lau, D. Sciberras, P. Deutsch, P. H. Howarth (Southampton, Terlings Park, Harlow, United Kingdom; Rahway, United States Of America). Prostaglandin D₂ a mediator of nasal obstruction. Eur Respir J 2001; 16: Suppl. 31, 2881

Member's Comments

No comment yet.

Related content which might interest you: Prostaglandin D2 metabolite as a marker of asthma exacerbations Source: Eur Respir J 2002; 20: Suppl. 38, 424s Year: 2002 Prostaglandin D2 and the role of the DP1, DP2 and TP receptors in the control of airway reflex events Source: Eur Respir J 2015; 45: 1108-1118 Year: 2015 Antigen-induced formation of prostaglandin D2 in mouse asthma model Source: Eur Respir J 2005; 26: Suppl. 49, 578s Year: 2005 A novel protective role of prostaglandin D2 in antigen-induced bronchoconstriction Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020 Prostaglandin D2 (PGD2) and tryptase release into blood after adenosine and methacholine challenges in asthmatic patients Source: Eur Respir J 2006; 28: Suppl. 50, 670s Year: 2006 Involvement of eicosanoids and surfactant protein D in extrinsic allergic alveolitis Source: Eur Respir J 2005; 26: 1069-1073 Year: 2005 Downregulation of prostaglandin E2 in bronchial fibroblasts of asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 95s Year: 2002 Bronchoconstriction induced by prostaglandin D2 (PGD2) in guinea pig lung is enhanced by selective COX-2 inhibition Source: Eur Respir J 2006; 28: Suppl. 50, 759s Year: 2006 Prostaglandin D2 is a human airway smooth muscle chemoattractant Source: Eur Respir J 2006; 28: Suppl. 50, 338s Year: 2006 Prostaglandin E2 levels are elevated in nasal lavages from asthmatic patients with allergic rhinitis Source: Eur Respir J 2003; 22: Suppl. 45, 109s Year: 2003 Increased leukotriene and lower prostaglandin E2 concentrations in induced sputum of patients with eosinophilic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 733s Year: 2005 Effects of leukotriene receptor antagonists on airway mucus secretion Source: Eur Respir J 2001; 18: Suppl. 33, 245s Year: 2001 Fevipiprant inhibits eosinophil activation induced by multiple metabolites of prostaglandin D2 Source: International Congress 2019 – COPD, asthma and rhinitis: from cellular mechanisms to patients’ clinical responses Year: 2019 Effect of resolvin D1 on leukotriene D4-induced constriction of rat and human bronchioles Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Montelukast inhibits bronchoconstriction and gas exchange defects induced by leukotriene D4 challenge in asthma Source: Eur Respir J 2002; 20: Suppl. 38, 308s Year: 2002 Prostaglandin E2 prevents mast cell dependent bronchoconstrictrion via the EP2 receptor in human small airways Source: International Congress 2015 – Novel mechanisms and treatments in allergy and asthma Year: 2015 Inhibition of mast cell PGD2 release protects against mannitol-induced airway narrowing Source: Eur Respir J 2006; 27: 944-950 Year: 2006 Down-regulation of allergic reactions by stimulation of prostaglandin E receptor EP3 subtype Source: Annual Congress 2004 - Insights into asthma and COPD Year: 2004 Comparison of glucocorticoid and cysteinyl leukotriene receptor antagonist treatments in the airway remodeling induced by chronic airway inflammation in guinea pigs Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008